Feb 5, 2020: Nestlé Health Science and Valbiotis, a research and development company committed to scientific innovation for preventing and fighting metabolic diseases, have entered into a deliberate partnership for the development and commercialization of an innovative and patented product to reduce the risk of developing Type 2 Diabetes.
TOTUM-63 is the combination of 5 plant extracts specially designed in order to reduce the risk of developing Type 2 Diabetes on prediabetic subjects.
Sébastien Peltier, CEO of Valbiotis commented, “Nestlé Health Science is an ideal strategic partner for Valbiotis.
Its global reach, strategic intent to develop science-based nutritional health solutions and focus on fighting metabolic disorders like diabetes will be instrumental to TOTUM-63’s worldwide commercialization success.
We are excited about the opportunity that this deal brings to Valbiotis and to the many millions of people around the world at risk of becoming Type 2 diabetics.
This transformational deal arrives just five years after the creation of Valbiotis and is a recognition of the hard work, commitment and vision of our team.”
Under the terms of the agreement, Valbiotis grants exclusive and global commercial rights to Nestlé Health Science for the use of TOTUM-63 in the prediabetes and type 2 diabetes market.
The collaboration will support the work of Valbiotis in a number of ways, including
financing the most recent phase of clinical development before regulatory authorities in the
The United States and Europe approve health claims.
https://www.nestlehealthscience.com/newsroom/press-releases/agreement-to-develop-and-commercialize-totum-63
